Pasadena, California
United States
43
2026-02-05
40
2026-05-05
These are the the leading inventors for applications assigned to Xencor, Inc.:
Xencor, Inc. based in Pasadena, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#2 | 2025-12-09 ā Patent 12,492,253 granted on 2025-12-09Anti-human C5 antibodies
#3 | 2025-07-17 ā Patent 12,466,897 granted on 2025-11-11HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#4 | 2025-06-19ANTI-CD20 ANTIBODIES AND THERAPEUTIC USES THEREOF
#5 | 2025-04-10DOSING OF A BISPECIFIC ANTIBODY THAT BINDS PD1 AND CTLA4
#6 | 2024-12-19 ā Patent 12,404,329 granted on 2025-09-02HETERODIMERIC ANTIBODIES THAT BIND PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CD3
#7 | 2024-12-05 ā Patent 12,398,207 granted on 2025-08-26HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6
#8 | 2024-08-08BIOMARKERS, METHODS, AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASE INCLUDING SYSTEMIC LUPUS ERYTHEMATOUS (SLE)
#9 | 2024-07-04 ā Patent 12,378,326 granted on 2025-08-05ANTI-CD28 X ANTI-PSMA ANTIBODIES
#10 | 2024-03-21 ā Patent 12,415,849 granted on 2025-09-16HETERODIMERIC PROTEINS
#11 | 2024-01-18 ā Patent 12,378,313 granted on 2025-08-05BISPECIFIC BINDING AGENTS BINDING TO CLDN18.2 AND CD3
#12 | 2023-11-16 ā Patent 12,359,002 granted on 2025-07-15HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#13 | 2023-10-26 ā Patent 12,448,423 granted on 2025-10-21TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
#14 | 2023-09-07 ā Patent 12,509,495 granted on 2025-12-30LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
#15 | 2023-08-24 ā Patent 12,365,743 granted on 2025-07-22ANTI-CD28 X ANTI-PSMA ANTIBODIES
#16 | 2023-07-20 ā Patent 12,497,457 granted on 2025-12-16METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#17 | 2023-02-16 ā Patent 11,987,636 granted on 2024-05-21Dosing of a bispecific antibody that binds CD20 and CD3
#18 | 2023-01-26 ā Patent 11,655,277 granted on 2023-05-23IL-12 heterodimeric Fc-fusion proteins
#19 | 2022-12-22 ā Patent 12,129,309 granted on 2024-10-29Heterodimeric antibodies that bind CD3 and CD38
#20 | 2022-12-15 ā Patent 12,234,270 granted on 2025-02-25IL-12 heterodimeric Fc-fusion proteins
#21 | 2022-12-01 ā Patent 11,718,667 granted on 2023-08-08Optimized antibody variable regions
#22 | 2022-11-03 ā Patent 12,486,311 granted on 2025-12-02NOVEL CTLA4-IG IMMUNOADHESINS
#23 | 2022-09-29 ā Patent 11,859,012 granted on 2024-01-02Heterodimeric antibodies that bind CD3 and GPC3
#24 | 2022-09-15 ā Patent 11,739,144 granted on 2023-08-29Heterodimeric antibodies that bind CD3 and CLDN6
#25 | 2022-07-07 ā Patent 11,981,717 granted on 2024-05-14Engineered IL-2 Fc fusion proteins
#26 | 2022-06-30 ā Patent 12,152,076 granted on 2024-11-26Bispecific and monospecific antibodies using novel anti-PD-1 sequences
#27 | 2022-05-26 ā Patent 11,945,880 granted on 2024-04-02Heterodimeric antibodies that bind CD3 and tumor antigens
#28 | 2022-05-26 ā Patent 12,054,545 granted on 2024-08-06Heterodimeric antibodies that bind somatostatin receptor 2
#29 | 2022-04-21 ā Patent 11,919,956 granted on 2024-03-05Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
#30 | 2022-04-14 ā Patent 12,215,165 granted on 2025-02-04Fc variants with altered binding to FcRn
#31 | 2022-03-31 ā Patent 11,919,958 granted on 2024-03-05Anti-CD28 compositions
#32 | 2022-03-10 ā Patent 12,139,525 granted on 2024-11-12Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
#33 | 2022-02-10 ā Patent 12,239,688 granted on 2025-03-04IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof
#34 | 2021-11-18 ā Patent 11,851,466 granted on 2023-12-26Targeted IL-12 heterodimeric Fc-fusion proteins
#35 | 2021-10-07 ā Patent 11,840,579 granted on 2023-12-12Bispecific antibodies that bind to CD38 and CD3
#36 | 2021-09-09 ā Patent 11,932,685 granted on 2024-03-19Fc variants with altered binding to FcRn
#37 | 2021-08-19 ā Patent 12,180,302 granted on 2024-12-31Heterodimeric antibodies that bind fibroblast activation protein
#38 | 2021-07-29 ā Patent 11,932,675 granted on 2024-03-19PD-1 targeted IL-15/IL-15RĪ± Fc fusion proteins with improved properties
#39 | 2021-06-10 ā Patent 11,814,423 granted on 2023-11-14Heterodimeric proteins
#40 | 2021-06-10 ā Patent 12,006,345 granted on 2024-06-11Untargeted and targeted IL-10 Fc-fusion proteins
#41 | 2021-06-03 ā Patent 11,634,506 granted on 2023-04-25Heterodimeric proteins
#42 | 2021-05-13 ā Patent 11,820,830 granted on 2023-11-21Optimized Fc variants
#43 | 2021-04-08 ā Patent 11,673,972 granted on 2023-06-13Heterodimeric antibodies that bind CD3 and tumor antigens
Also check out Xencor, Inc.'s (Pasadena, United States) applicant profile with 68 patent applications submitted.
339553 ā